Aerovate is a clinical stage biopharmaceutical company focused on
developing drugs that meaningfully improve the lives of patients with rare
cardiopulmonary disease. Aerovate’s initial focus is on advancing its Phase 2b candidate AV-101, its
dry powder inhaled formulation of the drug imatinib for the treatment of
pulmonary arterial hypertension.